EP0628056A4 - HUMAN IMMUNOGLOBULIN DIRECTED FOR THE PREVENTION AND TREATMENT OF STAPHYLOCOCCIA. - Google Patents

HUMAN IMMUNOGLOBULIN DIRECTED FOR THE PREVENTION AND TREATMENT OF STAPHYLOCOCCIA.

Info

Publication number
EP0628056A4
EP0628056A4 EP93901435A EP93901435A EP0628056A4 EP 0628056 A4 EP0628056 A4 EP 0628056A4 EP 93901435 A EP93901435 A EP 93901435A EP 93901435 A EP93901435 A EP 93901435A EP 0628056 A4 EP0628056 A4 EP 0628056A4
Authority
EP
European Patent Office
Prior art keywords
staphylococcia
prevention
treatment
human immunoglobulin
immunoglobulin directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP93901435A
Other languages
German (de)
French (fr)
Other versions
EP0628056A1 (en
Inventor
Gerald W Fischer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Original Assignee
Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry M Jackson Foundation for Advancedment of Military Medicine Inc filed Critical Henry M Jackson Foundation for Advancedment of Military Medicine Inc
Publication of EP0628056A1 publication Critical patent/EP0628056A1/en
Publication of EP0628056A4 publication Critical patent/EP0628056A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/18—Testing for antimicrobial activity of a material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/305—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F)
    • G01N2333/31—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Micrococcaceae (F) from Staphylococcus (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP93901435A 1992-02-25 1992-11-09 HUMAN IMMUNOGLOBULIN DIRECTED FOR THE PREVENTION AND TREATMENT OF STAPHYLOCOCCIA. Withdrawn EP0628056A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80431792A 1992-02-25 1992-02-25
US804317 1992-02-25
PCT/US1992/009830 WO1993017044A1 (en) 1992-02-25 1992-11-09 Directed human immune globulin for the prevention and treatment of staphylococcal infections

Publications (2)

Publication Number Publication Date
EP0628056A1 EP0628056A1 (en) 1994-12-14
EP0628056A4 true EP0628056A4 (en) 1997-03-05

Family

ID=25188685

Family Applications (1)

Application Number Title Priority Date Filing Date
EP93901435A Withdrawn EP0628056A4 (en) 1992-02-25 1992-11-09 HUMAN IMMUNOGLOBULIN DIRECTED FOR THE PREVENTION AND TREATMENT OF STAPHYLOCOCCIA.

Country Status (5)

Country Link
EP (1) EP0628056A4 (en)
JP (1) JPH08504167A (en)
AU (1) AU673508B2 (en)
CA (1) CA2117480A1 (en)
WO (1) WO1993017044A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4124816B2 (en) * 1992-03-19 2008-07-23 ヘンリー エム．ジャクソン ファウンデーション フォー ザ アドバンスメント オブ ミリタリー メディスン Broadly reactive opsonin antibodies that react with normal staphylococcal antigens
US6660842B1 (en) 1994-04-28 2003-12-09 Tripep Ab Ligand/receptor specificity exchangers that redirect antibodies to receptors on a pathogen
US6933366B2 (en) 1996-12-27 2005-08-23 Tripep Ab Specificity exchangers that redirect antibodies to bacterial adhesion receptors
JPH0840932A (en) 1994-07-29 1996-02-13 Kitasato Inst:The Antigenic vaccine and therapeutic antibody for Staphylococcus spp. And method for producing the same
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US7250494B2 (en) 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
KR20050099536A (en) 2003-02-06 2005-10-13 트리펩 아베 Glycosylated specificity exchangers
US7335359B2 (en) 2003-02-06 2008-02-26 Tripep Ab Glycosylated specificity exchangers
US20090214584A1 (en) * 2005-05-31 2009-08-27 Biostapro Ab Characterization of novel lpxtg-containing proteins of staphylococcus epidermidis
EA016268B1 (en) * 2009-05-12 2012-03-30 Государственное Учреждение ''Республиканский Научно-Практический Центр Трансфузиологии И Медицинских Биотехнологий'' Method for producing antistaphylococcol blood plasma
FR2989589A1 (en) * 2012-04-20 2013-10-25 Univ Paris Curie PREVENTION AND TREATMENT OF NON-VIRAL INFECTIONS IN INDIVIDUALS TREATED BY IMMUNOSUPPRESSANTS

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1499035A (en) * 1975-04-10 1978-01-25 Ts Nii Gematologii I Perelivan Antistaphylococcus human immune globulin and method of preparing same
JPS5452794A (en) * 1977-09-30 1979-04-25 Kousaku Yoshida Extracting of polysacchride from capusle containing epidermis staphylococus

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
C.P. TIMMERMAN ET AL.: "Characterisation and functional aspects of monoclonal antibodies specific for surface proteins of coagulase-negative staphylococci", THE JOURNAL OF MEDICAL MICROBIOLOGY, vol. 35, 13 August 1991 (1991-08-13), pages 65 - 71, XP000613626 *
GERALD W. FISCHER ET AL.: "Directed immune globulin enhances survival in an intralipid induced neonatal model of lethal Staphylococcus epidermidis sepsis", PEDIATRIC RESEARCH, vol. 29, no. 4, April 1991 (1991-04-01), pages 281A, XP000613632 *
See also references of WO9317044A1 *
THEODORE J. CIESLAK ET AL.: "Post-immunization antibodies to S. epidermidis are broadly reactive and opsonic", PEDIATRIC RESEARCH, vol. 31, no. 4, April 1992 (1992-04-01), pages 275A, XP000613625 *
VAN OSS, CAREL J. ET AL: "Immunoglobulins as aspecific opsonins. III. Opsonizing power of fragments of polyclonal and monoclonal immunoglobulin G", RES J. RETICULOENDOTHEL. SOC. (1973), 13(3), 221-30 CODEN: RESJAS, 1973, XP000613681 *

Also Published As

Publication number Publication date
JPH08504167A (en) 1996-05-07
AU673508B2 (en) 1996-11-14
EP0628056A1 (en) 1994-12-14
AU3271893A (en) 1993-09-13
WO1993017044A1 (en) 1993-09-02
CA2117480A1 (en) 1993-09-02

Similar Documents

Publication Publication Date Title
GR3036347T3 (en) Compounds useful for treating allergic and inflammatory diseases.
EP0634930A4 (en) Compounds useful for treating allergic and inflammatory diseases.
MX9101046A (en) NOVEL ANTIBODIES FOR THE TREATMENT AND PREVENTION OF INFECTION OF ANIMALS AND MAN
FR2739255B1 (en) PEST CONTROL COMPOSITION FOR THE TREATMENT AND PROTECTION OF PETS
FR2685206B1 (en) IMPLANTABLE DRAINAGE DEVICE FOR THE TREATMENT OF HYDROCEPHALIA.
FI934782A7 (en) Ultrasound treatment system
FR2656220B1 (en) AGENTS BLOCKING THE EFFECT OR FORMATION OF THE EDRF FACTOR FOR THE TREATMENT OF SHOCK.
FR2663044B1 (en) APPARATUS FOR THE TREATMENT OF SURFACES.
ZA965938B (en) Use of MP52 of MP121 for the treatment and prevention of diseases of the nervous system.
FI951163A7 (en) Waste treatment
NO912548D0 (en) PROCEDURE FOR TREATMENT OF WASTE PRODUCTS.
EP0577243A3 (en) Recombinant monoclonal antibodies, neutralizing HIV for the prevention and treatment of HIV infections.
FR2697754B1 (en) Method and machine for the treatment of medical waste.
FR2746658B1 (en) IMPLANTABLE DRAINAGE VALVE FOR THE TREATMENT OF HYDROCEPHALIA
FI930494A7 (en) WASTE TREATMENT SYSTEM
ZA921094B (en) Treatment of particulate material.
FR2690152B1 (en) PROCESS FOR THE PREPARATION AND TREATMENT OF PROPELLANTS.
FR2612775B1 (en) COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF SKIN DEGENERATION
NO905291D0 (en) PROCEDURE FOR THE TREATMENT OF ZINCED BY-PRODUCTS AND WASTE MATERIALS.
MA23837A1 (en) BENZAMIDES FOR THE TREATMENT OF NEUROLOGICAL DEGENERES
FR2658419B1 (en) MEDICAMENT FOR THE TREATMENT OF DERMATITIS.
DE69101847D1 (en) Preparation for the prevention or treatment of hypertriglyceridemia.
EP0679083A4 (en) PREVENTION AND TREATMENT OF SEPTICEMIA.
DE69306831D1 (en) Treatment of liquids
EP0653208A3 (en) Substance P antagonists for the treatment and prevention of solar erythema.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940824

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FISCHER, GERALD W.

RHK1 Main classification (correction)

Ipc: C12P 21/08

A4 Supplementary search report drawn up and despatched

Effective date: 19970117

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19980917

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19991201